Revelation Biosciences Inc (REVB) News

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

- Abstract Includes Positive Data from a Recently Completed Preclinical Ischemia Reperfusion Acute Kidney Injury Model - Revelation Biosciences...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement...

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

- Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study - Revelation Biosciences Inc...

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...

Form 8-K - Current report